Reassessment of risk and vaccine efficacy through genotyping analysis of genital warts: are genital warts truly benign?

You have accessJournal of UrologyCME1 Apr 2023MP15-06 REASSESSMENT OF RISK AND VACCINE EFFICACY THROUGH GENOTYPING ANALYSIS OF GENITAL WARTS: ARE GENITAL WARTS TRULY BENIGN? Eun Jae Kim, Jae Chul Lee, Don Hee Lyu, Useok Choi, Kang Sup Kim, Bong Hee Park, Hong Chung, Won Yeol Cho, Chang Hee Han, and Sangrak Bae Eun Jae KimEun Jae Kim More articles by this author , Jae Chul LeeJae Chul Lee More articles by this author , Don Hee LyuDon Hee Lyu More articles by this author , Useok ChoiUseok Choi More articles by this author , Kang Sup KimKang Sup Kim More articles by this author , Bong Hee ParkBong Hee Park More articles by this author , Hong ChungHong Chung More articles by this author , Won Yeol ChoWon Yeol Cho More articles by this author , Chang Hee HanChang Hee Han More articles by this author , and Sangrak BaeSangrak Bae More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003235.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The purpose of this study is to re-evaluate the risk by analyzing the virus that caused genital warts through the genotype analysis of human papillomavirus performed during the treatment of genital warts, and to investigate the possibility of responding to each vaccine type. METHODS: From January, 2020 to June 2021, three urology clinics and hospitals were visited and the results of patients diagnosed with genital warts and HPV genotyping analysis were analyzed. According to the provided results, it was divided into 'high risk' and 'low risk', and if they coexist, it was classified as 'mixed'. Each was analyzed according to the number of lesions and whether or not there was a second recurrence. In addition, it was analyzed whether it was possible to completely cope with each type of vaccine. Analysis was also performed according to the patient's age, site, and recurrence. RESULTS: The analysis results of a total of 692 patients were confirmed. The average age was 33 years, 671 males and 21 females. There were 356 (51.44%) cases in the pure low-risk group, 233 (33.67%) cases in the mixed group, and 103 (14.88%) cases in the pure high-risk group. By major virus, type 6 was the most common with 400 cases (57.8%), and type 11 was identified with 138 (19.94%), 16 with 51 (7.37%), and 52 with 48 (6.94). There were 302 patients who were completely cured by the 4-valent vaccine and 348 patients with 9-valent vaccine, showing an increase in coping ability against additional viruses by 15.2% when changing from 4-valent to 9-valent. Of the 262 recurrence cases, pure low 139 (53.05%), pure high 44 (16.79%), mixed 79 (30.15%), and primary lesion were 430 cases, pure low 217 (50.46%), pure high 59 (12.77%), mixed 154 (33.48%). CONCLUSIONS: Type 6 was the most common type, but in the 20-35 year old group, more than 50% of the genital warts were identified as a mixed. An additional effect of 15.2% can be expected when changing from a quadrivalent to a nine-valent. There was no difference in relapse according to the risk, but in the case of a single lesion, the possibility of the high-risk group was high. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e193 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Eun Jae Kim More articles by this author Jae Chul Lee More articles by this author Don Hee Lyu More articles by this author Useok Choi More articles by this author Kang Sup Kim More articles by this author Bong Hee Park More articles by this author Hong Chung More articles by this author Won Yeol Cho More articles by this author Chang Hee Han More articles by this author Sangrak Bae More articles by this author Expand All Advertisement PDF downloadLoading ...